PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Fonseca, R., Kuroda, J., Ishida, T., Popat, R., Huang, J. S., Yver, A., Vandendries, E., Elmeliegy, M., Ma, W. D., Sborov, D. W.
Publicado 2022

Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial

por Laffel, L. M. B., Tamborlane, W. V., Yver, A., Simons, G., Wu, J., Nock, V., Hobson, D., Hughan, K. S., Kaspers, S., Marquard, J.
Publicado 2018

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

por Daud, A. I., Xu, C., Hwu, W.-J., Urbas, P., Andrews, S., Papadopoulos, N. E., Floren, L. C., Yver, A., DeConti, R. C., Sondak, V. K.
Publicado 2010